Skip to main content
SpringerLink
Log in

The elephant in the room: the high cost of progress in oncology

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Djalalov S, et al. Cost Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : 24 Feb 2014. Available from: URL: http://dx.doi.org/10.1200/JCO.2013.53.1186.

    PubMed  Google Scholar 

  2. Kelly RJ, et al. Cost-Effectiveness of Crizotinib for Anaplastic Lymphoma Kinase-Positive, Non-Small-Cell Lung Cancer: Who Is Going to Blink at the Cost? Journal of Clinical Oncology : 24 Feb 2014. Available from: URL: http://dx.doi.org/10.1200/JCO.2013.54.6002.

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The elephant in the room: the high cost of progress in oncology. PharmacoEcon Outcomes News 698, 9 (2014). https://doi.org/10.1007/s40274-014-1112-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1112-8

Search

Navigation